Department of Dermatology, College of Medical Sciences, Bharatpur, Nepal.
Cancer Med. 2020 May;9(10):3604-3612. doi: 10.1002/cam4.2995. Epub 2020 Mar 16.
The risk of prostate cancer in melanoma patients has been frequently assessed. However, a comprehensive meta-analysis specifically examining this association is lacking. Our aim was to quantify the risk of prostate cancer in melanoma patients based on the available evidence.
A systematic review of the existing literature was performed in PubMed, Scopus, and Cochrane databases by two authors independently. Studies reporting the effect size in the form of standardized incidence ratio (SIR) were used for quantitative analyses.
Of 17 studies included in the review, a total of 15 studies with 282 592 male melanoma patients were used for the analysis. Random-effects meta-analysis found a 24% increased risk (SIR = 1.24, 95% confidence interval 1.18 to 1.30) of prostate cancer in melanoma patients compared to the general population, with a prediction interval of 1.05 to 1.45. The risk was consistently significant for various geographical regions and latitude. Heterogeneity was significant (I = 75%).
These results suggest that the incidence of prostate cancer is significantly higher in patients with melanoma compared to the general population.
前列腺癌在黑色素瘤患者中的风险已被频繁评估。然而,缺乏专门针对这种关联的综合荟萃分析。我们的目的是根据现有证据量化黑色素瘤患者患前列腺癌的风险。
两位作者独立在 PubMed、Scopus 和 Cochrane 数据库中进行了现有文献的系统综述。使用以标准化发病比(SIR)形式报告效应大小的研究进行定量分析。
在综述中纳入的 17 项研究中,共有 15 项研究纳入了 282592 名男性黑色素瘤患者用于分析。随机效应荟萃分析发现,与普通人群相比,黑色素瘤患者患前列腺癌的风险增加了 24%(SIR=1.24,95%置信区间 1.18 至 1.30),预测区间为 1.05 至 1.45。不同地理区域和纬度的风险均一致显著。异质性显著(I=75%)。
这些结果表明,与普通人群相比,黑色素瘤患者前列腺癌的发病率显著更高。